PD-L1 inhibitor

Phase 2Small molecule

BBuzzard Pharmaceuticals

PD-L1 inhibitor is one of 11 small molecule programs targeting Collecting Duct Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Collecting Duct CarcinomaRecruiting

ResectableRecruiting

Advanced Refractory Solid TumorsNot yet recruiting

Collecting Duct CarcinomaPhase 2

Recruiting

ResectablePhase 2

Recruiting

Advanced Refractory Solid TumorsPhase 2

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Resectable

#DrugCompanyPhaseTrials

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 2

Almonertinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 2

1 3

PD-L1 inhibitor

BBuzzard Pharmaceuticals

Phase 2

1 4

Qinlock

DDeciphera Pharmaceuticals, LLC

Preclinical

1 5

Grazoprevir/elbasvir

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Collecting Duct Carcinoma

NCT06211114

Q4 2027

Phase 2Not yet recruiting

Advanced Refractory Solid Tumors

NCT07327411

Q1 2028

Phase 2Recruiting

Resectable

NCT07364305

Recruiting

Lung Cancer

NCT06869239

Clinical

Trials by Indication[1]

Lung Cancer2 trials

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Unknown status·TThe Affiliated Hospital of Qingdao University·Phase 1/2·NCT05325684·30 enrolled

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

Recruiting·PPeking University Cancer Hospital & Institute··NCT06869239·65 enrolled

Patients With Solid Tumors1 trial

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Completed·BBuzzard Pharmaceuticals·Phase 1/2·NCT04121442·15 enrolled

Advanced Refractory Solid Tumors1 trial

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07327411·40 enrolled

Collecting Duct Carcinoma1 trial

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06211114·30 enrolled

Resectable1 trial

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC

Recruiting·—·Phase 2·NCT07364305·50 enrolled

1 more indication

Advanced Solid Tumors1 trial

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05530200·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PD-L1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-L1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-L1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Buzzard Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBuzzard Pharmaceuticals

PD-L1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Lung Cancer2 trials

Patients With Solid Tumors1 trial

Advanced Refractory Solid Tumors1 trial

Collecting Duct Carcinoma1 trial

Resectable1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News